- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | J&J scores EU approval for Tecvayli combo in second line | ||
| Fr | AI, genomics expert leaves Pathos AI, will advise Pfizer | ||
| Fr | Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor | ||
| Fr | Akeso and CStone secure China clearances for next-generation ADCs | ||
| Fr | Bioptimus, Cancer Research Horizons partner on AI-powered precision medicine | ||
| Do | Claude Science outperforms experts in protein binder task | ||
| Do | Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa | ||
| Do | Trump taps White House aide Heidi Overton to lead FDA | ||
| Do | $31.1m ARPA-H funding for Siemens endovascular robotics | ||
| Do | Akiram, ITM sign Lutetium-177 supply agreement | ||
| Mi | FDA greenlights Regeneron drug for rare bone disease | ||
| Mi | MSD, Moderna skin cancer vaccine scores historic phase 3 win | ||
| Mi | $50m Network Bio launch & NVIDIA collaboration | ||
| Mi | Medable, Tufts CSDD value AI gain at $21m net per programme | ||
| Mi | LEO Pharma pens $435m deal for Tanabe Pharma's dersimelagon | ||
| Di | BioMarin snaps up Alesta's lead asset for $275M | ||
| Di | AstraZeneca's volrustomig hits Phase 3 setback in lung cancer | ||
| Di | Sandoz adds 10 biosimilars through $322m Henlius deal | ||
| Di | MHRA clarifies UK position on microbiome-based medicines | ||
| Di | Australia first for Hansa's Idefirix in commercial kidney transplant | ||
| Mo | After failure in sickle cell, Fulcrum Therapeutics merges with Slate Medicines | ||
| Mo | Sanofi to lay off 229 Blueprint employees, close offices | ||
| Mo | OpenAI Foundation pledges $100m to boost hepatitis C cure rates | ||
| Mo | Capricor's DMD hope still strong, as it shares financials | ||
| Mo | Tauklarify PET approval for Lantheus in AD NFT pathology |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.